Details

NameSymbolSector
MEDI-CAPS LTD.MEDICAPQPharmaceuticals
Open
38
High
38
Low
36.9
Close
37.39
Volume
479
Exchange
bse
Time
03-Oct-2025

Outlook

Score:  

0

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Medi-caps is  
None
Estimated Stoploss of Medi-caps is ₹  
38
Medi-caps has a  
Bearishℹ
 pattern. 
Formation of  
None
 candle pattern indicates the trend direction of Medi-caps is  
Unpredictableℹ
. 

Trend

Medi-caps is in  
Sideways trendℹ
. 
Price of Medi-caps is  
Downℹ
 by  

5.77

%. 
Target
Buy @ 

36.3

Sell @ 

45.42

Current @ 

37.39

Volume

The trade volumes of Medi-caps have become  
Deficientℹ
The volume trend for Medi-caps is  
Bearishℹ
, but the participants are  
Weak Sellersℹ
The trade volume of Medi-caps is  

Down

 by  

82.83

% 

Valuation

The current market price of Medi-caps is  
Overvaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 125cr and total assets worth ₹ 125cr, the balance sheet of Medi-caps is:  
Balancedℹ
. 
Cashflow
Medi-caps has  
Insufficientℹ
 cash flow because it is  

₹ 0cr

. It is  
Downℹ
 by  

0

%. 

(*Mar 2025)

55.56% i.e. ₹ 5cr earned in operatingℹ
44.44% i.e. ₹ 4cr spent in investingℹ
0% in financingℹ
0% in otherℹ
Medi-caps has  
Insufficientℹ
 cash flow because it is  

₹ 0cr

. It is  
Upℹ
 by  

100

%. 

(*Mar 2024)

46.15% i.e. ₹ 6cr earned in operatingℹ
53.85% i.e. ₹ 7cr spent in investingℹ
0% in financingℹ
0% in otherℹ
Income
The income of Medi-caps is  

₹ 3cr

 and  

Loss

 is :  

₹ 3cr

(*Jun 2025)

Medi-caps Losses increased by:  

400

% and Income is Down by:  

66.67

% 

(*Jun 2025)

The income of Medi-caps is  

₹ 9cr

 and  

Profit

 is :  

₹ 1cr

(*Mar 2025)

Medi-caps Profit is up by:  

150

% and Income is Up by:  

125

% 

(*Mar 2025)

The income of Medi-caps is  

₹ 4cr

 and  

Loss

 is :  

₹ 2cr

(*Dec 2024)

Medi-caps Losses increased by:  

200

% and Income is Down by:  

50

% 

(*Dec 2024)

By using this site you agree to the use of cookies to deliver a better site experience.